Mutual of America Capital Management LLC Buys 652 Shares of Hologic, Inc. (NASDAQ:HOLX)

Mutual of America Capital Management LLC raised its stake in shares of Hologic, Inc. (NASDAQ:HOLXGet Rating) by 2.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,074 shares of the medical equipment provider’s stock after acquiring an additional 652 shares during the period. Mutual of America Capital Management LLC’s holdings in Hologic were worth $2,361,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Veritable L.P. lifted its stake in Hologic by 3.2% during the 1st quarter. Veritable L.P. now owns 4,721 shares of the medical equipment provider’s stock valued at $363,000 after acquiring an additional 145 shares in the last quarter. Bfsg LLC raised its stake in shares of Hologic by 0.7% during the 2nd quarter. Bfsg LLC now owns 23,305 shares of the medical equipment provider’s stock worth $1,615,000 after purchasing an additional 155 shares during the period. Glassman Wealth Services raised its stake in shares of Hologic by 59.6% during the 2nd quarter. Glassman Wealth Services now owns 415 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 155 shares during the period. DB Fitzpatrick & Co Inc raised its stake in shares of Hologic by 1.6% during the 2nd quarter. DB Fitzpatrick & Co Inc now owns 10,256 shares of the medical equipment provider’s stock worth $711,000 after purchasing an additional 160 shares during the period. Finally, Quent Capital LLC raised its stake in shares of Hologic by 22.3% during the 1st quarter. Quent Capital LLC now owns 887 shares of the medical equipment provider’s stock worth $68,000 after purchasing an additional 162 shares during the period. 85.70% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Hologic

In other news, General Counsel John M. Griffin sold 26,902 shares of the business’s stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $76.12, for a total transaction of $2,047,780.24. Following the completion of the transaction, the general counsel now owns 168,944 shares of the company’s stock, valued at $12,860,017.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Karleen Marie Oberton sold 14,545 shares of the business’s stock in a transaction dated Tuesday, November 1st. The stock was sold at an average price of $72.50, for a total transaction of $1,054,512.50. Following the completion of the transaction, the chief financial officer now owns 126,811 shares of the company’s stock, valued at $9,193,797.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel John M. Griffin sold 26,902 shares of the business’s stock in a transaction dated Monday, November 14th. The stock was sold at an average price of $76.12, for a total value of $2,047,780.24. Following the transaction, the general counsel now directly owns 168,944 shares of the company’s stock, valued at approximately $12,860,017.28. The disclosure for this sale can be found here. Insiders own 1.54% of the company’s stock.

Hologic Stock Up 1.0 %

HOLX stock opened at $74.26 on Wednesday. The company has a quick ratio of 3.45, a current ratio of 4.12 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $18.26 billion, a PE ratio of 14.50, a PEG ratio of 1.40 and a beta of 1.01. Hologic, Inc. has a twelve month low of $59.78 and a twelve month high of $80.49. The stock has a 50-day simple moving average of $67.62 and a two-hundred day simple moving average of $70.25.

Hologic (NASDAQ:HOLXGet Rating) last posted its earnings results on Monday, October 31st. The medical equipment provider reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.20. The business had revenue of $953.30 million during the quarter, compared to analyst estimates of $861.68 million. Hologic had a return on equity of 31.85% and a net margin of 26.77%. The company’s quarterly revenue was down 27.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.61 EPS. On average, equities analysts predict that Hologic, Inc. will post 3.46 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. William Blair reiterated an “outperform” rating on shares of Hologic in a research note on Tuesday, November 1st. Cowen lowered their target price on Hologic from $88.00 to $86.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 1st. Mizuho lifted their target price on Hologic from $75.00 to $77.00 and gave the stock a “buy” rating in a research note on Tuesday, November 1st. Cowen lowered their target price on Hologic from $88.00 to $86.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 1st. Finally, Morgan Stanley lifted their price objective on Hologic from $68.00 to $74.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 1st. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $78.18.

About Hologic

(Get Rating)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.

Recommended Stories

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.